<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-134596" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Stiff Person Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muranova</surname>
            <given-names>Alexandra</given-names>
          </name>
          <aff>University of South Alabama</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shanina</surname>
            <given-names>Elena</given-names>
          </name>
          <aff>University of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexandra Muranova declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elena Shanina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-134596.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Stiff person syndrome (SPS) is a rare progressive and often underdiagnosed immune-mediated disorder of the central nervous system characterized by progressive rigidity and triggered painful spasms of predominantly axial and proximal limb muscles. The condition has an insidious onset with gradual worsening over time and, if left untreated, can lead to permanent disability and mortality. This activity reviews the evaluation and treatment of patients with SPS and emphasizes the importance of the interprofessional approach to managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of stiff person syndrome (SPS).</p></list-item><list-item><p>Describe the clinical presentation and diagnostic criteria of stiff person syndrome (SPS).</p></list-item><list-item><p>Summarize the management options for stiff person syndrome (SPS).</p></list-item><list-item><p>Outline the importance of early recognition of patients with stiff person syndrome (SPS) and an interprofessional approach to improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=134596&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=134596">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-134596.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Stiff person syndrome (SPS) is a rare disorder of the central nervous system characterized by rigidity and stimulus triggered painful muscle spasms of predominantly axial and proximal limb muscles. It was first described in 1956 by Frederick Moersch and Henry Woltman based on a case series of 14 patients with progressive fluctuating tightness of the spinal, abdominal, and thigh muscles. This condition was formerly named stiff-man syndrome and is also known as Moersch-Woltman Syndrome.&#x000a0;&#x000a0;</p>
        <p>The current clinical classification of SPS includes:</p>
        <list list-type="order">
          <list-item>
            <p>Classic SPS</p>
          </list-item>
          <list-item>
            <p>Partial SPS variants</p>
          </list-item>
          <list-item>
            <p>Progressive encephalomyelitis with rigidity and myoclonus (PERM).<xref ref-type="bibr" rid="article-134596.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Classic SPS is the most common clinical form, present in 70&#x000a0;to 80% of SPS patients. It is associated with anti-glutamic acid decarboxylase (anti-GAD) antibodies.&#x000a0;<xref ref-type="bibr" rid="article-134596.r2">[2]</xref>&#x000a0;The condition has an insidious onset with gradual worsening over time and often leads to permanent disability and, in some cases, mortality. SPS may coexist with other autoimmune disorders, including&#x000a0; Diabetes Mellitus Type 1 (DM-1), autoimmune thyroid disease, pernicious anemia, celiac disease, vitiligo.<xref ref-type="bibr" rid="article-134596.r3">[3]</xref>&#x000a0;</p>
        <p>Several clinical variants of SPS have been described and include stiff limb syndrome, jerky SPS, cerebellar variant, SPS with epilepsy, and dystonia.<xref ref-type="bibr" rid="article-134596.r1">[1]</xref><xref ref-type="bibr" rid="article-134596.r3">[3]</xref>&#x000a0;The paraneoplastic variant is associated with breast, colon, thyroid, lung malignancies, Hodgkin and non-Hodgkin lymphomas and tends to clinically manifest before cancer itself.&#x000a0;<xref ref-type="bibr" rid="article-134596.r2">[2]</xref>&#x000a0;</p>
        <p>PERM, first described in 1956, is known as SPS-plus syndrome. Patients have the rigidity of axial and limb muscles, diffuse myoclonus in addition to prominent autonomic instability.<xref ref-type="bibr" rid="article-134596.r3">[3]</xref></p>
        <p>There is increasing evidence for immune-mediated etiology of this disorder. Identification of associated antibodies and common comorbidities with other autoimmune diseases and malignancies has been important for a better understanding of disease mechanisms and approaches to treatment.</p>
      </sec>
      <sec id="article-134596.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>SPS is an autoimmune condition associated with high titers of autoantibodies to various components of inhibitory synapses, which leads to their impaired functioning through a low level of gamma-aminobutyric acid (GABA) on pre-synaptic or post-synaptic neuronal junctions.&#x000a0;</p>
        <p>The paraneoplastic form accounts for 5% to 10% of all cases and is characterized by the presence of antibodies to amphiphysin and less frequently to gephyrin. The most common malignancy associated with paraneoplastic variant includes breast adenocarcinoma followed by adenocarcinoma of the colon, small-cell lung carcinoma, malignancies of thymus and thyroid gland, and Hodgkin&#x02019;s lymphoma.<xref ref-type="bibr" rid="article-134596.r3">[3]</xref></p>
        <p>Genetic predisposition has been determined by the presence of DQB1 and DRB1 MHC-II alleles which increase the risk of idiopathic and paraneoplastic variants of SPS.<xref ref-type="bibr" rid="article-134596.r4">[4]</xref></p>
      </sec>
      <sec id="article-134596.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The estimated prevalence of classic SPS in the general population is 1&#x000a0;to 2 cases per million, with females being affected twice&#x000a0;as often as males, regardless of race.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref>&#x000a0;Most patients develop symptoms between the ages of 20 and 60, most commonly in their thirties and forties. PERM usually occurs in older adults between their fifties and sixties. Only 5% of cases of SPS have been reported in children.<xref ref-type="bibr" rid="article-134596.r6">[6]</xref></p>
      </sec>
      <sec id="article-134596.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of SPS has been explained by B-cell-mediated autoimmune inflammation that affects different components of inhibitory GABAergic neurons and their synapses.&#x000a0;Production of autoantibodies against antigens involved in GABA synthesis and release within the central nervous system results in a dysfunction of major inhibitory pathways leading to impaired truncal and axial muscles' impaired relaxation due to hyperexcitability the motor cortex. Glutamic acid decarboxylase (GAD) is an intracellular enzyme that transforms glutamate into GABA and is a primary target and the most common antigen identified in classic SPS.<xref ref-type="bibr" rid="article-134596.r7">[7]</xref>&#x000a0;GAD exists in 2 isoforms: GAD67 and GAD65. The baseline production of GABA is regulated by GAD67, while the second isoform provides additional GABA when there is an increased demand.<xref ref-type="bibr" rid="article-134596.r4">[4]</xref><xref ref-type="bibr" rid="article-134596.r8">[8]</xref></p>
        <p>Primarily, the production of anti-GAD65 antibodies is a hallmark of a pathological process in classic SPS and is found in 70-80% of cases. In addition to classic SPS, anti-GAD antibodies have been associated with other autoimmune neurological disorders, including limbic encephalitis, autoimmune epilepsy, cerebellar ataxia, myoclonus, and nystagmus. They now comprise GAD antibody-spectrum disorders (GAD-SD).<xref ref-type="bibr" rid="article-134596.r9">[9]</xref>&#x000a0;It is currently unclear if different epitope binding patterns can cause diverse clinical presentations of GAD-SD. Low titers of anti-GAD antibodies also are seen in patients with DM-1, and up to 30% of patients with GAD-SD, including SPS, have DM-1. However, high titers of anti-GAD antibodies are seen only in GAD-SD.<xref ref-type="bibr" rid="article-134596.r10">[10]</xref>&#x000a0;</p>
        <p>Additional antigens described with SPS include GABA(A) receptor-associated protein (GABARAP), dipeptidyl-peptidase-like protein-6 (DPPX) as well as glycine receptor (GlyR), which is associated with PERM.<xref ref-type="bibr" rid="article-134596.r11">[11]</xref></p>
        <p>A paraneoplastic variant of SPS is associated with antibodies against amphiphysin or gephyrin. Amphiphysin is an intracellular presynaptic protein involved in the endocytosis of the vesicle membrane and regulates the expression of GABA receptors at the axon membrane. It is demonstrated that antibodies against amphiphysin can decrease the amount of GABA receptors by reducing the endocytosis of the GABA-containing vesicles. Therefore, this diminishes the presynaptic vesicle pool and leads to impaired GABA transmission.<xref ref-type="bibr" rid="article-134596.r2">[2]</xref><xref ref-type="bibr" rid="article-134596.r12">[12]</xref></p>
      </sec>
      <sec id="article-134596.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Some of the characteristic histopathologic features of SPS include loss of GABAergic neurons in the spinal cord and cerebellum with scattered areas of inflammatory changes. Additionally, chromatolysis and vacuolization of anterior horn cells of the lower spinal cord segments were also described.<xref ref-type="bibr" rid="article-134596.r13">[13]</xref><xref ref-type="bibr" rid="article-134596.r14">[14]</xref><bold>&#x000a0;</bold>Paraneoplastic SPS is associated with more pronounced inflammatory changes in the temporal lobes, brainstem, and spinal cord.<xref ref-type="bibr" rid="article-134596.r15">[15]</xref></p>
      </sec>
      <sec id="article-134596.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Classic SPS</bold>
</p>
        <p>Classic SPS is a condition with an insidious onset and gradual progression over few months. It usually starts with rigidity and stiffness of the trunk muscles, specifically in the thoracolumbar region, due to continuous contraction of both abdominal and paraspinal muscles. Patients describe difficulties bending and turning, feeling that they walk like a &#x0201c;tin-man.&#x0201d; Later, the rigidity spreads to proximal upper and lower extremities.<xref ref-type="bibr" rid="article-134596.r10">[10]</xref>&#x000a0;Eventually, it leads to multiple chronic orthopedic abnormalities such as increased lumbar lordosis, joint deformities, and abnormal posturing, which results in a &#x0201c;statue-like&#x0201d; appearance and is accompanied by gait disturbances and multiple falls. In addition, patients develop painful generalized muscle spasms and exaggerated startle responses precipitated by unexpected tactile, visual, or acoustic stimuli and strong emotions. Patients often develop depression, task-specific phobias, fear of open spaces, anticipatory anxiety due to triggered spasms, and pathological startling.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref>&#x000a0;</p>
        <p>Due to common psychiatric comorbidities, SPS is being misdiagnosed for a functional neurological disorder or a primary psychiatric condition.&#x000a0;Patients usually have diurnal fluctuations of symptoms, worse with physical and emotional stress, cold weather, and infection. Distal and facial muscles are spared until later in the disease course. The frequency and duration of painful spasms vary.&#x000a0;In some cases, severe spasms can last for hours ("status spasticus"), often requiring an emergency room visit for treatment intravenous muscle relaxants. In rare cases, respiratory muscles can be involved.<xref ref-type="bibr" rid="article-134596.r16">[16]</xref></p>
        <p>
<bold>Partial SPS Variants</bold>
</p>
        <p>Stiff limb syndrome presents with isolated limb spasms and mostly spared trunk muscles. Abnormal posturing of the distal limb can resemble dystonia. Stiffness can eventually involve other muscles, but it remains most severe in one limb. In stiff trunk syndrome, spasms involve only axial musculature, sparing extremities. Rarely extraocular abnormalities with oscillopsia, opsoclonus, and nystagmus were reported.<xref ref-type="bibr" rid="article-134596.r16">[16]</xref>&#x000a0;Patients with cerebellar variant (SPS-Cer) present with dysmetria, gait ataxia, and nystagmus superimposed on stiffness.<xref ref-type="bibr" rid="article-134596.r17">[17]</xref></p>
        <p>
<bold>Paraneoplastic SPS</bold>
</p>
        <p>It was described by some authors that paraneoplastic SPS demonstrates more significant stiffness in the neck and upper extremities. These patients usually show a faster response to therapy and significant clinical improvement once their malignancy is removed.<xref ref-type="bibr" rid="article-134596.r8">[8]</xref>&#x000a0;</p>
        <p>
<bold>Progressive Encephalomyelitis with Rigidity and Myoclonus</bold>
</p>
        <p>PERM is a more severe variant of SPS, and it is characterized by relapsing-remitting course and more extensive involvement of different parts of the CNS, including the brainstem. This results in decreased consciousness or altered mentation, extraocular muscle dysfunction, ataxia, and autonomic failure.<xref ref-type="bibr" rid="article-134596.r8">[8]</xref><xref ref-type="bibr" rid="article-134596.r5">[5]</xref></p>
      </sec>
      <sec id="article-134596.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A diagnosis of SPS is usually made clinically by thorough neurological examination with the support of electrodiagnostic and laboratory findings.<xref ref-type="bibr" rid="article-134596.r8">[8]</xref>&#x000a0;Diagnostic criteria for SPS evolved over the years, and most accepted are criteria revised by Dalakas&#x000a0;in 2009.<xref ref-type="bibr" rid="article-134596.r18">[18]</xref></p>
        <p>The current diagnostic criteria for classic SPS&#x000a0; include:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Stiffness in the limb and axial muscles, prominent in the abdomen and thoracolumbar region</p>
          </list-item>
          <list-item>
            <p>Painful spasms precipitated by unexpected tactile and auditory stimuli</p>
          </list-item>
          <list-item>
            <p>Evidence of the continuous motor unit activity in agonist and antagonist muscles demonstrated by EMG</p>
          </list-item>
          <list-item>
            <p>Absence of other neurological impairments that could support an alternative diagnosis</p>
          </list-item>
          <list-item>
            <p>Positive serology for anti-GAD65&#x000a0;or&#x000a0;anti-amphiphysin autoantibodies</p>
          </list-item>
          <list-item>
            <p>Clinical response to therapy with benzodiazepines</p>
          </list-item>
        </list>
        <p>The level of anti-GAD antibodies in serum higher than 10,000IU/mL supports a clinical impression of SPS.<xref ref-type="bibr" rid="article-134596.r10">[10]</xref><bold>&#x000a0;</bold>CSF analysis is usually unremarkable. In patients with PERM, a mild increase in CSF cell count with elevated protein and positive oligoclonal bands has been demonstrated as well as positive autoantibodies against glycine receptors.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref>&#x000a0;</p>
        <p>Electrodiagnostic testing is useful to rule out other nerve and muscle pathologies and to confirm the clinical diagnosis.&#x000a0;Routine nerve conduction studies in SPS are usually normal.&#x000a0;Needle electromyography (EMG) in SPS shows continuous involuntary motor unit activity even at rest, despite volitional effort to relax. Continuous motor unit activity and co-activation of agonists-antagonists muscles are key diagnostic features and are mostly detected in trunk muscles, especially paraspinal and abdominal muscles and proximal limb muscles.<xref ref-type="bibr" rid="article-134596.r2">[2]</xref></p>
        <p>MRI brain and spinal cord are usually non-diagnostic in classic SPS, but they are often performed to rule out other causes of rigidity and stiffness.</p>
        <p>Magnetic resonance spectroscopy can show a focal change in GABA levels in the motor area of the brain in SPS.<xref ref-type="bibr" rid="article-134596.r19">[19]</xref><bold>&#x000a0;</bold>In patients with PERM, MRI might show hyperintense signals in the spinal cord and the brainstem.<xref ref-type="bibr" rid="article-134596.r8">[8]</xref>&#x000a0;</p>
        <p>To diagnose a paraneoplastic variant, it is important to check for antibodies against amphiphysin and gephyrin and initiate a prompt neoplastic workup.</p>
        <p>Since around 35 % of patients diagnosed with SPS have DM-1 and about 5 % have associated autoimmune thyroid disease, a search for coexisting autoimmune conditions is commonly performed.</p>
      </sec>
      <sec id="article-134596.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment options for SPS can be divided into two main categories: symptomatic and disease-modifying or immunotherapy.<xref ref-type="bibr" rid="article-134596.r3">[3]</xref><bold>&#x000a0;</bold>These lines of therapy are commonly used in combinations, depending on the severity of the disease.</p>
        <p>Symptomatic management is a standard of initial therapy and focuses on decreasing stiffness, rigidity, and painful muscle spasms. It is achieved using medications that promote GABA effects, such as benzodiazepines, baclofen, gabapentin, and vigabatrin. Diazepam is known to be a first-line symptomatic agent for patients with SPS. Still, it is not uncommon to develop a tolerance and addiction to benzodiazepines over time, resulting in a loss of its beneficial effects. Intrathecal baclofen is also effectively used in some patients. Other commonly used muscle relaxants include dantrolene and tizanidine.<xref ref-type="bibr" rid="article-134596.r2">[2]</xref>&#x000a0;Symptom management also includes treatment of co-existing seizures and psychiatric comorbidities with anti-epileptic and antidepressant medications, respectively.</p>
        <p>Disease-modifying therapy is a specific immune-modulating treatment that aims at reducing or removing autoantibodies. Intravenous immunoglobulin (IVIG) is proven to be the most effective immunotherapy in SPS,&#x000a0;promoting a clinical improvement for up to 1 year after a standard course of five sessions. Unlike IVIG, the benefit of plasma exchange is not yet fully established, and most patients only demonstrate temporary or no improvement in symptoms.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref><xref ref-type="bibr" rid="article-134596.r20">[20]</xref>&#x000a0;</p>
        <p>Corticosteroid effectiveness is controversial in SPS.&#x000a0;Rituximab, a monoclonal antibody against CD20 antigen on B-cells, has provided a long-lasting benefit in non-randomized trials.<xref ref-type="bibr" rid="article-134596.r21">[21]</xref>&#x000a0;Use of other immunomodulating agents including mycophenolate mofetil, azathioprine, cyclophosphamide, cyclosporine, tacrolimus, and sirolimus is reported with variable effects.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref></p>
      </sec>
      <sec id="article-134596.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for SPS is broad, and it includes disorders of the brain, spinal cord, and muscles:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myelopathy: compressive, inflammatory, infectious, ischemic</p>
          </list-item>
          <list-item>
            <p>Myopathies and muscular dystrophies</p>
          </list-item>
          <list-item>
            <p>Idiopathic Parkinson disease and Parkinson-plus syndromes</p>
          </list-item>
          <list-item>
            <p>Autoimmune encephalitis</p>
          </list-item>
          <list-item>
            <p>Primary lateral sclerosis</p>
          </list-item>
          <list-item>
            <p>Progressive multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Generalized or focal dystonia</p>
          </list-item>
          <list-item>
            <p>Neuromyotonia</p>
          </list-item>
          <list-item>
            <p>Isaac syndrome</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis</p>
          </list-item>
          <list-item>
            <p>Hereditary spastic paraplegia</p>
          </list-item>
          <list-item>
            <p>Hereditary hyperekplexia</p>
          </list-item>
          <list-item>
            <p>Leukodystrophies</p>
          </list-item>
          <list-item>
            <p>Neuroleptic malignant syndrome, serotonin syndrome, or malignant hypothermia</p>
          </list-item>
          <list-item>
            <p>Tetanus</p>
          </list-item>
          <list-item>
            <p>Functional neurological disorder</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-134596.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with SPS depends on multiple factors, including clinical presentation, the longitude of symptoms, co-existing neoplastic process, and a response to therapy. It is crucial to timely initiate therapy to prevent or lessen progression and avoid long-term complications. Most of the patients improve with medications, however fluctuations precipitated by physical and emotional stressors still occur. Despite the availability of multiple treatment options, some patients with SPS show disease progression over time, leading to permanent orthopedic abnormalities, inability to walk, and disability.<xref ref-type="bibr" rid="article-134596.r8">[8]</xref><xref ref-type="bibr" rid="article-134596.r5">[5]</xref>&#x000a0;In one longitudinal study, only 19% of patients could work after 4 years of follow-up.<xref ref-type="bibr" rid="article-134596.r16">[16]</xref>&#x000a0;Patients report markedly reduced quality of life due to physical and social limitations.</p>
      </sec>
      <sec id="article-134596.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with SPS are at higher risk of developing orthopedic problems such as lumbar hyperlordosis, joint deformities, and muscle atrophies, leading to abnormal posturing and gait abnormalities with increased fall risk. As the disease progresses, unexpected tactile and auditory stimuli could trigger the occurrence of autonomic failure with tachycardia,&#x000a0;&#x000a0;hypertension, and hyperthermia.<xref ref-type="bibr" rid="article-134596.r5">[5]</xref><xref ref-type="bibr" rid="article-134596.r8">[8]</xref></p>
      </sec>
      <sec id="article-134596.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>SPS is often an underdiagnosed or misdiagnosed condition that can lead to permanently impaired physical and mental health if not treated timely. Therefore, health care providers should aim at recognizing and managing the disease as early as possible and under the care of a neurology specialist. Patients with SPS would be best managed by an interprofessional team, including a physical therapist, psychiatrist, and orthopedic surgeon to increase their chance for recovery and preserve their quality of life. In addition, it is crucial to monitor patients who receive&#x000a0;immunotherapy for possible side effects. For patients with a paraneoplastic variant, a thorough search for underlying malignancy should be promptly initiated.&#x000a0;</p>
      </sec>
      <sec id="article-134596.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=134596&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=134596">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/stiff-person-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=134596">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/134596/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=134596">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-134596.s15">
        <title>References</title>
        <ref id="article-134596.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Ahlskog</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Stiff-man syndrome and variants: clinical course, treatments, and outcomes.</article-title>
            <source>Arch Neurol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-8</page-range>
            <pub-id pub-id-type="pmid">22332190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rakocevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.</article-title>
            <source>Muscle Nerve</source>
            <year>2012</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>623</fpage>
            <page-range>623-34</page-range>
            <pub-id pub-id-type="pmid">22499087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baizabal-Carvallo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Stiff-person syndrome: insights into a complex autoimmune disorder.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>840</fpage>
            <page-range>840-8</page-range>
            <pub-id pub-id-type="pmid">25511790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Immunology of stiff person syndrome and other GAD-associated neurological disorders.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>1043</fpage>
            <page-range>1043-53</page-range>
            <pub-id pub-id-type="pmid">24168411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadavi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noyce</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Giovannoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome.</article-title>
            <source>Pract Neurol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>272</fpage>
            <page-range>272-82</page-range>
            <pub-id pub-id-type="pmid">21921002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clardy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Renaud</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Childhood onset of stiff-man syndrome.</article-title>
            <source>JAMA Neurol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>1531</fpage>
            <page-range>1531-6</page-range>
            <pub-id pub-id-type="pmid">24100349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciccotto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome.</article-title>
            <source>Neurol Clin</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>319</fpage>
            <page-range>319-328</page-range>
            <pub-id pub-id-type="pmid">23186907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Abassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Villemarette-Pittman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>SPS: Understanding the complexity.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <day>15</day>
            <volume>404</volume>
            <fpage>137</fpage>
            <page-range>137-149</page-range>
            <pub-id pub-id-type="pmid">31377632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baizabal-Carvallo</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The neurological syndromes associated with glutamic acid decarboxylase antibodies.</article-title>
            <source>J Autoimmun</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>101</volume>
            <fpage>35</fpage>
            <page-range>35-47</page-range>
            <pub-id pub-id-type="pmid">31000408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsiortou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>17562864211003486</fpage>
            <pub-id pub-id-type="pmid">33854562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balint</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome and other immune-mediated movement disorders - new insights.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>496</fpage>
            <page-range>496-506</page-range>
            <pub-id pub-id-type="pmid">27262149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pauli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weishaupt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haselmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toyka</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Asan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition.</article-title>
            <source>Brain</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>139</volume>
            <issue>Pt 2</issue>
            <fpage>365</fpage>
            <page-range>365-79</page-range>
            <pub-id pub-id-type="pmid">26582558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm&#x000f8;y</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Skorstad</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>R&#x000f8;ste</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Scheie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alvik</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>111</volume>
            <issue>8</issue>
            <fpage>708</fpage>
            <page-range>708-12</page-range>
            <pub-id pub-id-type="pmid">19616370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witherick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Highley</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hadjivassiliou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pathological findings in a case of stiff person syndrome with anti-GAD antibodies.</article-title>
            <source>Mov Disord</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>2138</fpage>
            <page-range>2138-9</page-range>
            <pub-id pub-id-type="pmid">21611984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wessig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Toyka</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome.</article-title>
            <source>Neurology</source>
            <year>2003</year>
            <month>Jul</month>
            <day>22</day>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-8</page-range>
            <pub-id pub-id-type="pmid">12874398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rakocevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>03</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">30606131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rakocevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raju</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Semino-Mora</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies.</article-title>
            <source>Neurology</source>
            <year>2006</year>
            <month>Sep</month>
            <day>26</day>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1068</fpage>
            <page-range>1068-70</page-range>
            <pub-id pub-id-type="pmid">17000981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Stiff person syndrome: advances in pathogenesis and therapeutic interventions.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-10</page-range>
            <pub-id pub-id-type="pmid">19210912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Levy-Reis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Brain gamma-aminobutyric acid changes in stiff-person syndrome.</article-title>
            <source>Arch Neurol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>970</fpage>
            <page-range>970-4</page-range>
            <pub-id pub-id-type="pmid">15956168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ghani</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Morillo Cox</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Tambo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moya</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Stiff-Person Syndrome: A Treatment Update and New Directions.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Dec</month>
            <day>09</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>e11995</fpage>
            <pub-id pub-id-type="pmid">33437550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134596.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fawcett</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of stiff person syndrome with rituximab.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>7</issue>
            <fpage>999</fpage>
            <page-range>999-1001</page-range>
            <pub-id pub-id-type="pmid">15965211</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
